Professional Documents
Culture Documents
October 2018
Disclaimer
FORWARD-LOOKING STATEMENTS
This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation
and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company,” “we,” “us” and “our” refer to ViewRay, Inc.
Except for historical information, ViewRay’s written and accompanying oral presentation may contain forward-looking statements, including statements about the overall industry,
including but not limited to: our current expectations of the market; growth drivers; future trends; demand for radiation oncology products and features; and innovation and
growth opportunities. Forward-looking statements also include, but are not limited to, statements about ViewRay’s: future orders; backlog or earnings growth; future financial
results; and market acceptance of ViewRay’s existing products, future products or technology. Words such as “could,” “anticipates,” “expects,” “outlook,” “intends,” “plans,”
“believes,” “seeks,” “vision,” “estimates,” “may,” “will,” “future,” “horizon,” “aiming,” “driving,” “target” (or variations of them) and similar statements, are forward-looking
statements. These types of statements express management’s beliefs based on the information available to us as of the date of this presentation, are subject to change and are
not guarantees of future performance. Forward-looking statements involve risks, uncertainties and assumptions that are difficult to predict and could cause ViewRay’s results to
differ materially from those presented. These risks, uncertainties and assumptions include, but are not limited to, changes in: the regulatory environment; global economics; trade
compliance requirements, duties or tariffs; third-party reimbursement levels; currency exchange rates; taxation, healthcare law, and product clearance requirements, as well as
those related to: adverse publicity about ViewRay and our products; our reliance on sole or limited source suppliers; our ability to commercialize our products successfully; the
impact of competitive products and pricing, and all other risks listed from time to time in the company’s filings with the Securities and Exchange Commission, which are
incorporated into this Forward-Looking Statements disclosure by this reference. We do not assume any obligation to update or revise the forward-looking statements in
ViewRay’s written or oral presentation, whether based on future events, new or additional information or otherwise.
ViewRay’s written and oral presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of ViewRay’s securities in any state or
other jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or other jurisdiction.
ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches. Individual results may vary.
2
Driving a new standard of care in cancer
Powerful trend ➔ precise, minimally / non-invasive
therapies
3
Executive summary
Large Market Unique Technology
MRIdian MRIdian Linac >70 Scientific
8M Cancer cases diagnosed annually 1 FDA
Clearance
FDA
Clearance
Abstracts &
Publications
~$6.3B 2020 radiotherapy market (projected)
2
Targeted
chemotherapies
Macro trends in oncology moving
Robotic
surgery towards more precise and less
invasive treatments
MRI-guided
radiotherapy
~$6.3B
Initial targets
global radiotherapy market 1 Academic centers & early adopters
in 2020 (projected)
Global Linac
$4.6B
~ Market ~$2 – 2.5B annual target market 2
Soft tissue
MRIdian potential benefits
visualization
MRIdian SmartVISION™
Optimized dose delivery to tumor
Targeting to preserve
healthy tissue
Improved quality of life
MRIdian SmartTARGET™
6
An image is worth a thousand words
7
Disruptive, next gen technology
seamless integration of MRI and linac
CONE BEAM CT Linac MRIdian Linac
Potential limitations Potential benefits
MR imaging
Cone Beam CT adds dose to - Does NOT add dose
patient
- Additional radiation exposure Imaging DURING
treatment
Poor image quality - No need for invasive
- Need for seed implants or fiducials markers
8
SmartVISION: Soft tissue visualization
12
Early, promising results for the most challenging
cases
100%
2x Median
Survival 80%
MRIdian ROAR survival
% Overall Survival
Overall Toxicity
Increase 60%
0% Grade 3+
Toxicity
20%
0%
Non-adaptive RT toxicity
Higher Maximum Biologic Effective Dose Utilizing Adaptive MRI Guided Radiation Therapy Improves Survival of Inoperable
Pancreatic Cancer Patients 13
Rudra S, Jiang N, Rosenberg S, Olsen J, Lagerwaard F, Bruynzeel A, Parikh P, Bassetti M, Lee P; ASTRO 2017
Clearly differentiated technology
MRIdian
SEE
Visualize the tumor and
surrounding organs in high-
definition
SHAPE
Adapt each treatment for daily
anatomical changes
STRIKE
Image soft tissue during beam-on
with automated beam control
SIZE
Fit through existing door openings
and into standard linac vaults
14
Clearly differentiated technology
Other MRgRT
MRIdian
Technologies
SEE
Visualize the tumor and surrounding
organs in high-definition
SHAPE Aspirational.
Adapt each treatment for daily NO on-table adaptive
anatomical changes
functionality
STRIKE
Image soft tissue during beam-on Real-time imaging but
with automated beam control NO gating beam control
SIZE
Fit through existing door openings Requires wall and/or ceiling
and into standard linac vaults removal AND new 1.5m trench
15
Clearly differentiated technology
MRIdian Other MRgRT Conventional IGRT
Technologies Linacs
SEE
Visualize the tumor and Non-diagnostic, low-
surrounding organs in high- contrast soft tissue imaging
definition
STRIKE
Image soft tissue during Real-time imaging but NO soft tissue imaging
beam-on with automated NO gating beam control during beam-on
beam control
16
A thought leader speaks…
17
How we drive growth…
18
Commercial expansion
increase reach & resources to drive adoption
United States
Increase direct
representation and
EMEA bolster distribution
network
Japan
19
Technological innovation
protect & extend technology leadership
Speed
92
Issued patents
1, 2
Machine
vision
Biological
129
Patent applications
2
imaging
1 Licensed or owned (1 jointly owned)
2 Patent date effective 8/6/18 20
Clinical strategy
shaping care patterns, clinical guidelines & reimbursement policies
Aspirations
breast cancer
Fewer mastectomies
Improved cosmesis
Building clinical
prostate cancer compendium
Fewer prostatectomies
Reduce ED &
incontinence
lung cancer
Fewer lobectomies
Superior quality of life
21
Operational infrastructure
support & sustain growth
22
Driving a new standard of care in cancer
Powerful trend ➔ precise, minimally / non-invasive
therapies
23